Director/PDMR Shareholding

RNS Number : 0927V
Genedrive PLC
19 July 2018
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it on 17 July 2018 share options ("Options") were granted to certain of its directors to acquire a total of 486,306 ordinary shares of 1.5p each in the capital of the Company under the Company's 2017 Share Option Scheme.

 

The Options have been granted with an exercise price equal to the closing price on the day before grant and vest after a period of three years if certain performance criteria are met.  The Options are exercisable over the period of 10 years from the date of grant.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.         

Details of the person discharging managerial responsibilities / person closely associated

a.         

Name

1.   David Budd

2.   Matthew Fowler

 

 

2.         

Reason for the notification

a.         

Position/status

1.   CEO

2.   CFO

 

a.         

Initial notification

/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.         

Name

genedrive plc

b.         

LEI

213800ZYODIRZ87Y4K14

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the

Financial instrument, type

of instrument

Identification code

Options over ordinary shares of 1.5 pence each

b.         

Nature of the transaction

Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 5 December 2017.

c.         

Price(s) and volume(s)

 

Price(s)

 

Option price(s)

Volume(s)

David Budd

30.5p

222,260

Matthew Fowler

30.5p

264,046

d.         

Aggregated information

·      Aggregated volume

·      Price

 

 

N/A

 

e.         

Date of the transaction

2018-17-07; UTC time

f.         

Place of the transaction

Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO


Matthew Fowler: CFO


 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel


Oliver Jackson


 

Stanhope Capital Ltd

+44(0)203 815 8880

Patrick Claridge

 


 

Consilium Strategic Communications

+44 (0)203 709 5700

Chris Gardner


Matthew Neal


Laura Thornton


genedrive@consilium-comms.com


 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEANXPFFDPEFF

Companies

Genedrive (GDR)
UK 100

Latest directors dealings